Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of the Combination of GLPG2451 and GLPG2222, With or Without GLPG2737, in Adult Subjects With Cystic Fibrosis

Trial Profile

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of the Combination of GLPG2451 and GLPG2222, With or Without GLPG2737, in Adult Subjects With Cystic Fibrosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs GLPG 2222 (Primary) ; GLPG 2451 (Primary) ; GLPG 2737 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms FALCON
  • Sponsors Galapagos NV
  • Most Recent Events

    • 28 Jun 2018 According to a Galapagos NV media release, interim readout from this study is expected in Q3 2018.
    • 25 Apr 2018 According to a Galapagos NV media release, interim readout from this study is expected in 2018.
    • 24 Apr 2018 According to a Galapagos NV media release, top-line results from this study is expected in Q3 2018. This study is expected to expand at other European countries.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top